Management of Bladder Cancer following Solid Organ TransplantationReportar como inadecuado

Management of Bladder Cancer following Solid Organ Transplantation - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Advances in UrologyVolume 2011 2011, Article ID 256985, 7 pages

Clinical StudyDepartment of Urology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA

Received 16 July 2010; Revised 8 February 2011; Accepted 21 February 2011

Academic Editor: A. Stenzl

Copyright © 2011 Jeffrey J. Tomaszewski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. Present our experience managing bladder cancer following liver and renal transplantation. Methods. Single institution retrospective review of patients diagnosed with bladder urothelial carcinoma BUC following solid organ transplantation between January 1992 and December 2007. Results. Of the 2,925 renal and 2,761 liver transplant recipients reviewed, we identified eleven patients 0.2% following transplant diagnosed with BUC. Two patients with low grade T1 TCC were managed by TURBT. Three patients with CIS and one patient with T1 low grade BUC were treated by TURBT and adjuvant BCG. All four are alive and free of recurrence at a mean follow-up of 51 ± 22 months. One patient with T1 high grade BUC underwent radical cystectomy and remains disease free with a follow-up of 98 months. Muscle invasive TCC was diagnosed in four patients at a median of 3.6 years following transplantation. Two patients are recurrence free at 24 and 36 months following radical cystectomy. Urinary diversion and palliative XRT were performed in one patient with un-resectable disease. Conclusions. Bladder cancer is uncommon following renal and liver transplantation, but it can be managed successfully with local and-or extirpative therapy. The use of intravesical BCG is possible in select immunosuppressed patients.

Autor: Jeffrey J. Tomaszewski, Jeffrey A. Larson, Marc C. Smaldone, Matthew H. Hayn, and Stephen V. Jackman



Documentos relacionados